Asked by: Tony Lloyd (Labour - Rochdale)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he plans to respond to the letter dated 23 July 2021 from the hon. Member for Rochdale on treatment for lymphedema.
Answered by Edward Argar - Minister of State (Ministry of Justice)
We replied to the hon. Member on 8 March 2022.
Asked by: Tony Lloyd (Labour - Rochdale)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he plans to respond to the hon. Member for Rochdale’s correspondence dated 8 October 2021 regarding ICS Boards and dated 25 October 2021 regarding training for radiologists and oncologists.
Answered by Edward Argar - Minister of State (Ministry of Justice)
We replied to the hon. Member’s letter dated 8 October 2021 on 31 January 2022 and the letter dated 25 October 2021 on 16 March 2022.
Asked by: Tony Lloyd (Labour - Rochdale)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what funding the Government is making available for the treatment of brain tumours.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The information is not available in the format requested. Expenditure on the treatment of brain tumours forms part of system budgets for the National Health Service. Funding is made available to Cancer Alliances to deliver the NHS Long Term Plan’s ambitions for all cancers, including brain tumours.
Asked by: Tony Lloyd (Labour - Rochdale)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what funding is available for research into brain tumours; and what research streams on brain tumours the Government is allocating funding to.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
In May 2018 the Government announced a £40 million investment over five years for brain tumour research as part of the Tessa Jowell Brain Cancer Mission, through the National Institute for Health Research (NIHR). The NIHR released a public announcement to the research community, making clear our desire to receive brain tumour research funding applications. We are relying on researchers to submit high-quality research proposals.
As with other Government funders of health research, the NIHR does not allocate funding for specific disease areas. The level of research spend in a particular area is driven by factors such as scientific potential and the number and scale of successful funding applications. The NIHR welcomes funding applications for research into any aspect of human health, including brain tumour research.
Asked by: Tony Lloyd (Labour - Rochdale)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 July 2021 to Question 35705 on Motor Neurone Disease: Drugs, if he will provide details of the projects relating to Motor Neurone Disease that were funded by the National Institute for Health Research in each of the years between 2015 and 2020.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The information requested is shown in the following table. The National Institute for Health Research (NIHR) is also funding research on motor neurone disease through the NIHR’s research infrastructure, including the NIHR Sheffield Biomedical Research Centre. However this information is not available at individual study level.
Year | Project |
2015/16 | Telehealth in Motor Neurone Disease: the TiM trial. A randomised controlled pilot study of the use of the TiM system to deliver highly specialised care to patients and carers of those living with motor neurone disease. * Evaluation of the clinical and cost-effectiveness of Short-term Integrated Palliative Care Services (SIPC) to OPTimise CARE for people with advanced longterm Neurological conditions (OPTCARE Neuro) * |
2016/17 | Head up: The development of a novel cervical orthosis to support neck weakness due to neurological disease. * Telehealth in Motor Neurone Disease: the TiM trial. A randomised controlled pilot study of the use of the TiM system to deliver highly specialised care to patients and carers of those living with motor neurone disease. * |
2017/18 | Telehealth in Motor Neurone Disease: the TiM trial. A randomised controlled pilot study of the use of the TiM system to deliver highly specialised care to patients and carers of those living with motor neurone disease. * Evaluation of the clinical and cost-effectiveness of Short-term Integrated Palliative Care Services (SIPC) to OPTimise CARE for people with advanced longterm Neurological conditions (OPTCARE Neuro) * A feasibility study and randomised controlled trial of acceptance and COMmitment therapy for people with Motor nEuroN Disease (COMMEND) * |
2018/19 | Telehealth in Motor Neurone Disease: the TiM trial. A randomised controlled pilot study of the use of the TiM system to deliver highly specialised care to patients and carers of those living with motor neurone disease. * A feasibility study and randomised controlled trial of acceptance and COMmitment therapy for people with Motor nEuroN Disease (COMMEND) * Nusinersen for treating infant or child spinal muscular atrophy [ID1069] A programme to develop and evaluate a complex intervention to achieve a high calorie diet for people with Amyotrophic Lateral Sclerosis (HighCALS) * Enhancing the efficacy of non-invasive ventilation for patients with motor neurone disease: Synthesising the evidence, mapping the services and translating the evidence into clinical practice. * |
2019/20 | A feasibility study and randomised controlled trial of acceptance and COMmitment therapy for people with Motor nEuroN Disease (COMMEND) * A programme to develop and evaluate a complex intervention to achieve a high calorie diet for people with Amyotrophic Lateral Sclerosis (HighCALS) * Enhancing the efficacy of non-invasive ventilation for patients with motor neurone disease: Synthesising the evidence, mapping the services and translating the evidence into clinical practice. * Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473] - Part 1 |
2020/21 | A feasibility study and randomised controlled trial of acceptance and COMmitment therapy for people with Motor nEuroN Disease (COMMEND) * A programme to develop and evaluate a complex intervention to achieve a high calorie diet for people with Amyotrophic Lateral Sclerosis (HighCALS) * Enhancing the efficacy of non-invasive ventilation for patients with motor neurone disease: Synthesising the evidence, mapping the services and translating the evidence into clinical practice. * Onasemnogene abeparvovec for treating spinal muscular atrophy type 1[ID1473] - Part 2 Risdiplam for treating spinal muscular atrophy [ID1631] |
Note:
* Project funded for multiple years spanning the period 2015-2020.
Asked by: Tony Lloyd (Labour - Rochdale)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will hold discussions with the Chancellor of the Exchequer on increasing spending on targeted research on motor neurone disease ahead of the 2021 Spending Review.
Answered by Edward Argar - Minister of State (Ministry of Justice)
There are no plans for specific discussions. The Department funds research through the National Institute for Health Research (NIHR). It is not usual practice to ring-fence funding for particular topics or conditions. The NIHR welcomes funding applications for research into any aspect of human health, including motor neurone disease. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality. We are currently working on ways to significantly boost further research on dementia and neurodegeneration at all stages, including medical and care interventions.
Asked by: Tony Lloyd (Labour - Rochdale)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he plans to respond to the correspondence of 25 February 2021 from the hon. Member for Rochdale on the legislative proposals for a Health and Care Bill.
Answered by Edward Argar - Minister of State (Ministry of Justice)
We replied to the hon. Member on 3 September 2021.
Asked by: Tony Lloyd (Labour - Rochdale)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what representations he has received on (a) the efficacy of the Novavax vaccine following its trial and (b) whether volunteers who received two vaccinations as part of the Novavax trial are eligible to receive other types of approved covid-19 vaccines.
Answered by Nadhim Zahawi
The Medicines and Healthcare products Regulatory Agency (MHRA) has regular meetings with Novavax regarding their submission for the vaccine but this is not yet complete. A review of the quality, safety and efficacy data will be required before the MHRA and Commission on Human Medicines can consider approval of the vaccine.
As trial participants become eligible for the vaccination programme, they should discuss with the trial investigator to decide whether they should receive an approved COVID-19 vaccine. This should be informed by whether they had received a placebo or control vaccine, an active vaccine with known efficacy against COVID-19, an experimental trial vaccine product with no current efficacy data and whether they have received a full proposed or incomplete regimen. There is currently a lack of evidence to inform whether a subsequent dose of a different COVID-19 vaccine after a full regimen of experimental vaccine provides any benefit. Subjects should also be made aware that the risks of receiving the deployed vaccine after the trial vaccine are unknown.
Asked by: Tony Lloyd (Labour - Rochdale)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he plans to respond to the letter of 3 March 2021 from the hon. Member for Rochdale on differential pricing policies for covid-19 vaccinations.
Answered by Edward Argar - Minister of State (Ministry of Justice)
We replied to the hon. Member on 21 May 2021.
Asked by: Tony Lloyd (Labour - Rochdale)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he plans to respond to the letter dated 20 November 2020 from the hon. Member for Rochdale.
Answered by Edward Argar - Minister of State (Ministry of Justice)
We are working to provide all Members and external correspondents with accurate answers to their correspondence, as well as supporting the Government’s response to the unprecedented challenge of the COVID-19 pandemic.
The hon. Member’s letter will be answered as soon as possible.